Answers are grounded in this paper and cite their sources.
Experts discuss AI enhancing clinical trial management and risk assessment processes in vaccine development, suggesting improved efficiency.
"AI would take on the bureaucratic, operational, and repetitive work, allowing humans to focus their time on creativity, scientific reasoning, and critical thinking.” Charlotte Barker (Editor, Vaccine Insights) speaks with Demetris N Zambas (Global Head, Clinical Data and Information Sciences, Clinical Development and Operations, Pfizer R&D) and Lynne Cesario (Executive Director, Risk-Based Monitoring Program Lead and AI Program Lead, Pfizer) about the role of AI in risk-based management of clinical trials, and their approach to integrating these new tools into established teams and processes.
No takes yet. Share an insight, caveat, or question.
Zambas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: